PSOLAR, the Psoriasis Longitudinal Assessment and Registry, is a multicenter, longitudinal, intercontinental, disease-based registry used to identify adverse events from commonly used psoriasis drugs.1 An evaluation of the risk of serious infection from systemic psoriasis treatments was recently published using data from PSOLAR. Ninety-three institutional review boards or ethics committees reported into the registry from…
Search results for: certolizumab
Data Collection Drives Evaluation of Psoriasis Treatments
For six years, the Psoriasis Longitudinal Assessment and Registry (PSOLAR) has collected data to assess the infection risk for drugs treating systemic psoriasis.
First Biosimilar Drugs Approved in U.S., Canada
The first biosmilar products have been approved in the U.S. and Canada, following Europe’s early lead. Canada approved its first biosimilar monoclonal antibody (mAb) therapy, known as Inflectra (infliximab), on March 30, 2015.1 In Canada, biosimilars are being called subsequent entry biologic (SEB) agents. Inflectra is approved for treating patients with rheumatoid arthritis (RA), ankylosing…
2014 ACR/ARHP Annual Meeting: Rheumatology Drug Updates, Safety News
Plus, hydrocodone combination products and brodalumab
Drugs Studied for Use in Rheumatoid Arthritis, Weight Loss
Plus, rheumatology drug news from EULAR 2014
EULAR 2014: Research on Rheumatoid Arthritis, Spondyloarthritis
Latest findings on rheumatological drug therapies, including methotrexate for RA, tumor necrosis factor inhibitors for SpA
Spondyloarthritis: Clues to Earlier Recognition
Rheumatologists at the California Rheumatology Alliance 10th Annual Medical & Scientific Meeting discuss challenges to diagnosing, managing spondyloarthritides
Rheumatologists Make Progress Defining Spectrum of Axial Spondyloarthritis
New research clarifies terminology used for diagnosis, but questions remain around epidemiology, genetics and management of patients with axial skeletal inflammation
Rheumatology Drug Updates
Information on new approvals and medication safety that rheumatologists need to know
The American College of Rheumatology Helps Keep Three Biologics Off the SAD List
In October, the Centers for Medicare and Medicaid Services directed carriers to again include three biologics in Medicare Part B coverage. (posted Nov. 19)
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- Next Page »